Uma Sinha - Concepedia

Author

Uma Sinha

Portola Pharmaceuticals (United States)

Also Known As

Satish Rao, Sinha U, Sinha, Uma, U Sinha, U. K. Sinha, U. SINHA, U. Sinha, U.K. Sinha, UMA SINHA, Uma Sinha

149

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Portola Pharmaceuticals (United States)Millennium Engineering and Integration (United States)Oregon Health & Science University Nil Ratan Sircar Medical College and Hospital Medical University of South Carolina

About

Uma Sinha is an author at Portola Pharmaceuticals (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	31	1.7K
2	Natural Sciences	13	18	501
3	Biochemistry	13	16	506
4	Health Sciences	4	4	217
5	Biomolecular Engineering	3	3	123

Uma Sinha

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach, Nature Medicine ThrombosisVenous ThrombosisCardiovascular DiseaseIndirect InhibitorsMedicine	2013	689
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Julian D. Gillmore, Daniel P. Judge, Francesco Cappelli, New England Journal of Medicine	2024	365
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy Daniel P. Judge, Stephen B. Heitner, Rodney H. Falk, Journal of the American College of Cardiology	2019	244
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) Kenneth Bauer, Bruce L. Davidson, Michael Gent, Thrombosis and Haemostasis Total Knee ReplacementThrombosisPulmonary EmbolismVte IncidenceBetrixaban Dosage	2008	158
Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India Uma Sinha, Keshab Sinharay, Sudipta Saha, Indian Journal of Endocrinology and Metabolism	2013	140
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration Julia Hoellenriegel, Greg Coffey, Uma Sinha, Leukemia Hematological MalignancyLymphoid NeoplasiaReceptor Tyrosine KinaseImmunologyAdult T-cell Leukemia-lymphoma	2012	138
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model Michael P. Reilly, Uma Sinha, Pierrette André, Blood	2010	131
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) Stuart J. Connolly, John W. Eikelboom, Paul Dorian, European Heart Journal	2013	125
Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis Greg Coffey, Francis DeGuzman, Mayuko Inagaki, Journal of Pharmacology and Experimental Therapeutics	2011	116
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor Penglie Zhang, Wenrong Huang, Lingyan Wang, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBioorganic ChemistryBiochemistryMedicineNatural Sciences	2009	105

Page 1